Key Details
Price
$28.51Annual ROE
-1537.75%Beta
1.90Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor - Jefferies Sam Eiber - BTIG Anthony Pettinari - Citi Josh Jennings - TD Cowen Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs Third Quarter 2024 Earnings Conference Call.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for a.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation. “Today's approval is transformative for breast aesthetics in.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Establishment Labs missed consensus revenue and earnings estimates in Q3. The company also slashed its full-year guidance.
FAQ
- What is the ticker symbol for Establishment Labs Holdings?
- Does Establishment Labs Holdings pay dividends?
- What sector is Establishment Labs Holdings in?
- What industry is Establishment Labs Holdings in?
- What country is Establishment Labs Holdings based in?
- When did Establishment Labs Holdings go public?
- Is Establishment Labs Holdings in the S&P 500?
- Is Establishment Labs Holdings in the NASDAQ 100?
- Is Establishment Labs Holdings in the Dow Jones?
- When was Establishment Labs Holdings's last earnings report?
- When does Establishment Labs Holdings report earnings?
- Should I buy Establishment Labs Holdings stock now?